Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus

Study Summary

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (Part 1), and the safety, tolerability and PD of multiple doses of ARO-INHBE in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (Part 2).

Conditions

Obesity

Interventions / Drugs

ARO-INHBE Placebo Tirzepatide

View on ClinicalTrials.gov ↗

Sponsor

ARWR

Arrowhead Pharmaceuticals

RNAi Therapeutics

D36/100

Study Details

Enrollment120 participants

Primary Completion—

Lead SponsorArrowhead Pharmaceuticals

Data Retrieved2026-04-11 02:54:36.141204+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.